CN101856495B - Medical composition and mixture for treating chicken infectious bursal disease and preparation method thereof - Google Patents
Medical composition and mixture for treating chicken infectious bursal disease and preparation method thereof Download PDFInfo
- Publication number
- CN101856495B CN101856495B CN2009100645941A CN200910064594A CN101856495B CN 101856495 B CN101856495 B CN 101856495B CN 2009100645941 A CN2009100645941 A CN 2009100645941A CN 200910064594 A CN200910064594 A CN 200910064594A CN 101856495 B CN101856495 B CN 101856495B
- Authority
- CN
- China
- Prior art keywords
- mixture
- injection
- bursal disease
- water
- infectious bursal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medical composition and a mixture for treating chicken infectious bursal disease and a preparation method thereof. The medical composition (100 grams) comprises: 1 to 10 grams of astragalus polysaccharides, 3 to 12 grams of taurine, 4 to 15 grams of aminopyrine, 2 to 10 grams of vitamin C, 0.04 to 0.2 gram of interferon inducer, 5 to 20 grams of alcohol, 0.1 to 0.4 gram of sodium benzoate, and the balance of water for injection. The product is characterized by reasonable formula composition, stable physical and chemical properties, accurate dose, quick effect, long-lasting medicament effect, high bioavailability, safe use and exact treatment effect.
Description
Technical field
The invention belongs to the Chinese and Western medicine mixture of treatment infectious bursal disease, be specifically related to a kind of pharmaceutical composition of treating infectious bursal disease, mixture and preparation method thereof.
Background technology
Infectious bursal disease (Infectious bursal disease; IBD) be acute, the height contagious disease of the young chicken of harm; Its maximum harm is immune maincenter organ---the fabricius bursa that destroys chicken; Make bone-marrow-derived lymphocyte degeneration and necrosis, cause immunity of organism to suppress or immunological incompetence, make body reduce, the susceptibility of pathogen such as other antibacterial and virus is increased the immunoreation of other vaccine.It is fallen ill suddenly, propagates rapidly, and sickness rate is high, and tangible peak death curve is arranged, and is dead in infection beginning in the 3rd day usually, peaks, and stops very soon later in 5～7 days.Sick mortality rate is generally 15%～50%, and the virulent mortality rate can reach more than 70%.Its cardinal symptom for suffer from diarrhoea, tremble, extremely feeble, the pathological changes of fabricius bursa, kidney and lower limb flesh chest muscle are hemorrhage, glandular stomach and muscular stomach intersection strip are hemorrhage to be to have distinctive pathological changes.
At present; The countries and regions that primary disease is raised chickens in the world are widely current, and also are one of important infectious disease of the China of serious threat in recent years poultry husbandry, and mortality rate, mortality increase on the one hand; Cause immunosuppressant on the other hand; Multiple effective vaccine is descended to the immunne response of chicken, cause immuning failure, chicken is increased the cause of disease susceptibility.Primary disease normal with colibacillosis, newcastle, the mixed infection of mycoplasma gallinarum disease, mortality rate increases greatly, causes enormous economic loss.Particularly, popular some new features that occurred of infectious bursal disease in recent years show as morbidity age in days expanded range, and atypical case, mixed infection or syndrome increase, and mortality rate Gao Zheke reaches 90%.
Because infectious bursa of Fabricius virus is very stable in external environment, and heat-resisting especially, can be in hen house long-term existence, conventional sterilization and quarantine measures can not be controlled primary disease.Main preventive measure is vaccination.Because antigenic diversity between the appearance of superpower infectious bursa of Fabricius virus and various serotype and the variant makes vaccine immunity be difficult to obtain ideal effect, can cause other disease on the contrary sometimes in recent years, cause enormous economic loss to poultry husbandry.
At present, the specific medicament that does not still have treatment IBD on the market.Early stage sick chicken is adopted high immunity yolk antibody or hyper-immune serum treatment usually; Though certain curative effect is arranged; But both raw materials for production are not from SPF (specific pathogen free microorganism) chicken entirely, and all are vulnerable to condition effect such as preparation, storage and transport, the danger that effect is unstable or other disease is propagated in existence; Like egg drop syndrome, avian leukosis, mycoplasma etc., there is potential threat in aviculture.Mostly the medicine that is used to treat IBD in clinical is some Chinese powder medicines, and its crude fiber content is high, and the digestive tract of poultry is short, a little less than coarse-fibred digestion power, makes the effective ingredient stripping difficulty in the medicine, and effect is uncertain, causes waste.Therefore, a kind of new more efficiently medicine of searching is imperative.
Summary of the invention
The objective of the invention is to be to overcome above-mentioned weak point, the pharmaceutical composition of a kind of reasonable recipe, treatment infectious bursal disease evident in efficacy is provided.This pharmaceutical composition organically combines Chinese and western drugs, and the performance medicine is advantage separately, learns from other's strong points to offset one's weaknesses, and coordinates each other.
It is mixture of processing of primary raw material and preparation method thereof with the said composition that another object of the present invention provides a kind of.
The objective of the invention is to realize through following technical scheme:
The pharmaceutical composition of treatment infectious bursal disease of the present invention, said composition is made up of the component of following weight parts:
Astragalus polysaccharides 1～10 weight portion
Taurine 3～12 weight portions
Aminophenazone 4～15 weight portions
Vitamin C 2～10 weight portions
Interferon inducers 0.04～0.2 weight portion.
Described interferon inducers is any one in polyinosini, hemagglutinin or the Tilorone, is preferably polyinosini.
The mixture that contains the treatment infectious bursal disease of pharmaceutical composition of the present invention, contain the component of following weight in every 100g mixture:
Astragalus polysaccharides 1～10g
Taurine 3～12g
Aminophenazone 4～15g
Vitamin C 2～10g
Interferon inducers 0.04～0.2g
Ethanol 5～20g
Sodium benzoate 0.1～0.4g
Surplus is a water for injection.
Described interferon inducers is any one in polyinosini, hemagglutinin or the Tilorone, is preferably polyinosini.
The method for preparing of the mixture of treatment infectious bursal disease of the present invention is carried out according to the following steps:
(1) get the half the water for injection of recipe quantity and be heated to 60 ℃, add taurine, vitamin C and aminophenazone successively, dissolving adds the ethanol of recipe quantity fully, forms solution;
(2) get proper amount of water for injection astragalus polysaccharides is dissolved, form solution;
(3) get proper amount of water for injection sodium benzoate is dissolved, form solution;
(4) get an amount of water for injection interferon inducers is dissolved, form solution;
(5) solution of combining step 1,2 and 3 gained is transferred pH to 6.0～7.0 with sodium hydroxide, slowly adds step 4 gained solution, and the limit edged stirs, and the water for injection standardize solution filters, and the aseptic subpackaged bottle of going into to sterilize gets final product.
In the prescription of the present invention, astragalus polysaccharides can make animal spleen increase as ideal immunostimulant; The hyperplasia of spleen entoplasm; Enhancing antibody is synthetic, and antibody forming cell's number (being haemolysis plaque number) and haemolysis measured value are significantly increased, and serum immune globulin IgA, IgM, IgG level obviously increase; And can resist immunosuppressant influences such as meticortelone, humoral immune function is had facilitation; Simultaneously, astragalus polysaccharides can strengthen the cell physiological metabolism, improves macrophage activity, increases macrophage quantity in the body, increases macrophage phagocytic function; Astragalus polysaccharides can also promote the cell transformation of body endolymph; Promote the function of immunocytes such as T cell, B cell, NK cell, improve the ability that leukocyte oozes out interferon, improve the content of immunoglobulin; Suppress the breeding of virus, panimmunity defective disease is all had good preventive and therapeutic effect.
Aminophenazone belongs to the pyrazolone antipyretic analgesic; Through suppressing the synthetic of hypothalamus prostaglandin and discharging; Recover the normal reaction of thermotaxic centre receptive neuron and reach and bring down a fever and analgesic activity; Through the synthetic of prostaglandin in the inflammation-inhibiting local organization with discharge, stablize lysosome membrane simultaneously, influence cytophagous phagocytosis and reach antiinflammatory action.
Taurine is as a kind of endogenous aminoacid maincenter inhibitory transmitter, and scalable nervous tissue irritability has effects such as analgesic, calm, antiinflammatory, rheumatism, convulsion, can obviously improve the body non-specific immunity.
Interferon inducers has broad-spectrum antiviral and immunological enhancement, can duplicate the cellular immunization of enhancing body and antitumor action through what interferon stoped virus.
Vitamin C can improve leukocyte and phagocytic function, promotes reticuloendothelial system and antibody to form the ability of enhancing body anti-stress, thereby enhancing body resistance against diseases.
Chinese veterinarian thinks that infectious bursal disease belongs to the category of " pestilence ", and its etiology and pathogenesis is the pyretic toxicity invasion and attack, and pathogenic heat is not separated, and the blood system pathogenic heat is contained, and heat is YANG pathogen, is prone to impairment of body fluid liquid, causes the dehydration of disease fowl, thirsty drink, the absurd row of pathogenic heat forcing blood.Chickling morbidity back is refusing to eat happiness drink mostly, and other similar Chinese medicines are powder mostly, mix the feeding administration through spice, and not only the absorption of medicine can not get ensureing, even also digest and assimilate process after taking in, drug effect can not in time be brought into play; The present invention, can guarantee the intake of medicine, and bring into play curative effect as early as possible, and not have the danger of the pathogenic microorganism that spreads disease through mixing the administration of drink method through medication preparation is become oral liquid formulation.
Drug regimen heat-clearing and toxic substances removing ability of the present invention is strong, and heat clearing away approach variation has taken into full account the thermotaxic characteristics of poultry, and the pestilence of dispelling the heat, dispel alleviates the sense of discomfort of body; Western medicine composition in the side can be eliminated symptom rapidly, and mitigate the disease increases disease fowl appetite, promotes rehabilitation; Immunostimulant in the side and interferon inducers Combined application; Directly act on virus, when suppressing virus breeding, but the rapid induction body produces interferon; Regulate the immune function of body itself; Enhancing antibody forms, and strengthens the phagocytosis of macrophage to pathogen, thereby effectively kills pathogen.
The invention has the beneficial effects as follows: this medicine belongs to Chinese and Western medicine mixture, has the function of two-ways regulation immunity of organisms, for the treatment of infectious bursal disease provides new way.This medicine can be eliminated clinical symptoms rapidly, transfers the intrinsic disease-resistant mechanism of body (like immune system, complement system etc.) fast, removes immunosuppressant, thereby reaches the viricidal effect that presses down.
Research proof medicine of the present invention has significant protection and therapeutical effect to artificial challenge's bursal disease virus of chickens model; Clinical research confirmation medicine of the present invention has excellent curative to infectious bursal disease; Especially can remove heating that viral infection causes rapidly, improve symptom, promote that sick fowl recovers to search for food; Second day clinical symptoms alleviated rapidly after the general medication, and recovery from illness in 3～5 days is evident in efficacy.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is elaborated.
Embodiment 1
1. treat the pharmaceutical composition of infectious bursal disease, said composition is made up of the component of following weight parts:
Astragalus polysaccharides 1 weight portion
Taurine 3 weight portions
Aminophenazone 4 weight portions
Vitamin C 2 weight portions
Polyinosini 0.04 weight portion.
2. treat the mixture of infectious bursal disease, contain the component of following weight in every 100g mixture:
Astragalus polysaccharides 1g
Taurine 3g
Aminophenazone 4g
Vitamin C 2g
Polyinosini 0.04g
Ethanol 5g
Sodium benzoate 0.1g
Surplus is a water for injection.
3. the method for preparing of the mixture of treatment infectious bursal disease is carried out according to the following steps:
(1) water for injection of getting 40g is heated to 60 ℃, adds taurine 3g, Catergen g and aminophenazone 4g successively, and dissolving adds the ethanol of 5g fully, forms solution;
(2) water for injection of getting 10g forms solution with the dissolving of 1g astragalus polysaccharides;
(3) water for injection of getting 5g forms solution with the dissolving of 0.1g sodium benzoate;
(4) water for injection of getting 10g forms solution with the dissolving of 0.04g polyinosini;
(5) solution of combining step 1,2 and 3 gained is transferred pH to 6.0～7.0 with sodium hydroxide, slowly adds step 4 gained solution, and the limit edged stirs, and the water for injection standardize solution filters, and the aseptic subpackaged bottle of going into to sterilize gets final product.
Embodiment 2
1. treat the pharmaceutical composition of infectious bursal disease, said composition is made up of the component of following weight parts::
Astragalus polysaccharides 2 weight portions
Taurine 6 weight portions
Aminophenazone 8 weight portions
Vitamin C 5 weight portions
Polyinosini 0.1 weight portion.
2. treat the mixture of infectious bursal disease, contain the component of following weight in every 100g mixture:
Astragalus polysaccharides 2g
Taurine 6g
Aminophenazone 8g
Vitamin C 5g
Polyinosini 0.1g
Ethanol 10g
Sodium benzoate 0.3g
Surplus is a water for injection.
3. the method for preparing of the mixture of treatment infectious bursal disease is carried out according to the following steps:
(1) water for injection of getting 40g is heated to 60 ℃, adds taurine 2g, vitamin C 6g and aminophenazone 8g successively, and dissolving adds the ethanol of 10g fully, forms solution;
(2) water for injection of getting 10g forms solution with the dissolving of 2g astragalus polysaccharides;
(3) water for injection of getting 5g forms solution with the dissolving of 0.3g sodium benzoate;
(4) water for injection of getting 10g forms solution with the dissolving of 0.1g polyinosini;
(5) solution of combining step 1,2 and 3 gained is transferred pH to 6.0～7.0 with sodium hydroxide, slowly adds step 4 gained solution, and the limit edged stirs, and the water for injection standardize solution filters, and the aseptic subpackaged bottle of going into to sterilize gets final product.
Embodiment 3
1. treat the pharmaceutical composition of infectious bursal disease, said composition is made up of the component of following weight parts::
Astragalus polysaccharides 3 weight portions
Taurine 12 weight portions
Aminophenazone 5 weight portions
Vitamin C 3 weight portions
Polyinosini 0.05 weight portion.
2. treat the mixture of infectious bursal disease, contain the component of following weight in every 100g mixture:
Astragalus polysaccharides 3g
Taurine 12g
Aminophenazone 5g
Vitamin C 3g
Polyinosini 0.05g
Ethanol 15g
Sodium benzoate 0.2g
Surplus is a water for injection.
3. the method for preparing of the mixture of treatment infectious bursal disease is with embodiment 1.
Embodiment 4
1. treat the pharmaceutical composition of infectious bursal disease, said composition is made up of the component of following weight parts::
Astragalus polysaccharides 4 weight portions
Taurine 10 weight portions
Aminophenazone 6 weight portions
Vitamin C 4 weight portions
Hemagglutinin 0.2 weight portion.
2. treat the mixture of infectious bursal disease, contain the component of following weight in every 100g mixture:
Astragalus polysaccharides 4g
Taurine 10g
Aminophenazone 6g
Vitamin C 4g
Hemagglutinin 0.2g
Ethanol 20g
Sodium benzoate 0.3g
Surplus is a water for injection.
3. the method for preparing of the mixture of treatment infectious bursal disease is with embodiment 1.
Embodiment 5
1. treat the pharmaceutical composition of infectious bursal disease, said composition is made up of the component of following weight parts::
Astragalus polysaccharides 5 weight portions
Taurine 8 weight portions
Aminophenazone 9 weight portions
Vitamin C 10 weight portions
Tilorone 0.08 weight portion.
2. treat the mixture of infectious bursal disease, contain the component of following weight in every 100g mixture:
Astragalus polysaccharides 5g
Taurine 8g
Aminophenazone 9g
Vitamin C 10g
Tilorone 0.08g
Ethanol 8g
Sodium benzoate 0.4g
Surplus is a water for injection.
3. the method for preparing of the mixture of treatment infectious bursal disease is with embodiment 1.
Embodiment 6
1. treat the pharmaceutical composition of infectious bursal disease, said composition is made up of the component of following weight parts::
Astragalus polysaccharides 6 weight portions
Taurine 4 weight portions
Aminophenazone 10 weight portions
Vitamin C 9 weight portions
Polyinosini 0.12 weight portion.
2. treat the mixture of infectious bursal disease, contain the component of following weight in every 100g mixture:
Astragalus polysaccharides 6g
Taurine 4g
Aminophenazone 10g
Vitamin C 9g
Polyinosini 0.12g
Ethanol 12g
Sodium benzoate 0.4g
Surplus is a water for injection.
3. the method for preparing of the mixture of treatment infectious bursal disease is with embodiment 1.
Embodiment 7
1. treat the pharmaceutical composition of infectious bursal disease, said composition is made up of the component of following weight parts::
Astragalus polysaccharides 7 weight portions
Taurine 5 weight portions
Aminophenazone 11 weight portions
Vitamin C 8 weight portions
Hemagglutinin 0.14 weight portion.
2. treat the mixture of infectious bursal disease, contain the component of following weight in every 100g mixture:
Astragalus polysaccharides 7g
Taurine 5g
Aminophenazone 11g
Vitamin C 8g
Hemagglutinin 0.14g
Ethanol 18g
Sodium benzoate 0.3g
Surplus is a water for injection.
3. the method for preparing of the mixture of treatment infectious bursal disease is with embodiment 1.
Embodiment 8
1. treat the pharmaceutical composition of infectious bursal disease, said composition is made up of the component of following weight parts::
Astragalus polysaccharides 8 weight portions
Taurine 7 weight portions
Aminophenazone 12 weight portions
Vitamin C 7 weight portions
Polyinosini 0.16 weight portion.
2. treat the mixture of infectious bursal disease, contain the component of following weight in every 100g mixture:
Astragalus polysaccharides 8g
Taurine 7g
Aminophenazone 12g
Vitamin C 7g
Polyinosini 0.16g
Ethanol 6g
Sodium benzoate 0.2g
Surplus is a water for injection.
3. the method for preparing of the mixture of treatment infectious bursal disease is with embodiment 1.
Embodiment 9
1. treat the pharmaceutical composition of infectious bursal disease, said composition is made up of the component of following weight parts::
Astragalus polysaccharides 10 weight portions
Taurine 11 weight portions
Aminophenazone 15 weight portions
Vitamin C 6 weight portions
Polyinosini 0.18 weight portion.
2. treat the mixture of infectious bursal disease, contain the component of following weight in every 100g mixture:
Astragalus polysaccharides 10g
Taurine 11g
Aminophenazone 15g
Vitamin C 6g
Polyinosini 0.18g
Ethanol 9g
Sodium benzoate 0.1g
Surplus is a water for injection.
3. the method for preparing of the mixture of treatment infectious bursal disease is with embodiment 1.
Weight portion in the embodiment of the invention can be got gram, kilogram or other unit of weight.
Clinical efficacy test (one)
Choose 350 of the healthy test of 30 ages in days broiler, be divided into 7 groups at random, 50 every group.The test group chicken is implemented artificial counteracting toxic substances, and counteracting toxic substances dosage is collunarium, eye dripping, per os 0.5mL for oral administration.Control drug is the eliminating pestilence and relieving toxicity granule, lot number: 20080514, produce by Shandong veterinary drug manufacturing enterprise.Behind the chickling inoculative infection property bursal disease virus 48h; Show typical clinical symptoms successively, clinical diagnosis occurs carrying out after the symptom, pathology cuts open inspection and lab testing is diagnosed as the bursal disease positive, the beginning medication; 5d is a course of treatment; Medication finishes the back and observes 5d continuously, weighs in 10d, relatively the relative weight gain rate.
Efficacy assessment: 1. clinical symptoms: lassitude, wing is sagging, and feather is fluffy and disorderly, is afraid of cold, the decline of searching for food, morbidity chicken draining appearance, rice water appearance white feces, fecal pollution crissum feather, serious dehydration, the toe pawl is shrivelled, and drinking-water increases.
2. cut open the inspection pathological changes: cut open the visible chicken dehydration of dying of illness in inspection back, chest muscle and lower limb flesh have striated or ecchymosis; Glandular stomach and muscular stomach intersection have ulcer and ecchymosis, and intestinal mucosa is hemorrhage, and renomegaly is pale; Dilatation of ureter is full of white urate; The fabricius bursa enlargement is outward by the jelly of yellow transparent; Invaginate swelling, hemorrhage, in rheuminess thing or yellow cheesy thing are arranged; Morbidity later stage fabricius bursa atrophy or the attenuation of fabricius bursa cyst wall.
3. criterion of therapeutical effect: (1) mortality rate.At duration of test, the classical symptom and the death of bursal disease appears in chicken, and necropsy has the typical characteristic sexually transmitted disease (STD) to become, viral isolation identification, and serological test is positive, and calculates mortality rate according to the death toll in every treated animal.(2) effective percentage.Clinical symptoms is clearly better, and it is normal basically to search for food, drink water, and feces is normal basically; Cuing open inspection has a small amount of uratosis, and fabricius bursa size, color and luster basically normally all are judged to be effectively, calculate effective percentage in view of the above.(3) cure rate.Chicken prothymia after the duration of test medication, it is normal to search for food, drink water, and feather is glossy, and feces is normal; It is calm to cut open the no urate of inspection, and fabricius bursa size, color and luster normally all are judged to be healing.(4) rate of body weight gain.Every chicken body weight during according to when beginning and off-test is calculated the gain in weight of every chicken, calculates the average weight gain and the standard deviation of every group of test chicken then according to this.The relative weight gain rate is to calculate by the ratio of each medication group with the average weight gain of normal healthy controls group, and wherein the normal healthy controls settings is 100%.Concrete efficacy result is seen table 1.
Table 1 medicine of the present invention is to artificial challenge's chicken bursal disease reason model curative effect
| Medicine | Number of animals | Route of administration | Dosage | Effective percentage % | Cure rate % | 10 days average weightening finish kg | The relative weight gain rate % |
| Mixture high dose group of the present invention | 50 | Mix drink | 2mL/L | 92 | 85 | 2.00±0.12 | 94.29 |
| Dose groups in the mixture of the present invention | 50 | Mix drink | 1mL/L | 88 | 82 | 2.00±0.11 | 94.29 |
| Mixture low dose group of the present invention | 50 | Mix drink | 0.5mL/L | 80 | 76 | 1.95±0.11 | 85.71 |
| Mixture safe dose group of the present invention | 50 | Mix drink | 10mL/L | - | - | 2.06±0.13 | 104.29 |
| The medicine matched group | 50 | Mix drink | 1g/L | 66 | 52 | 1.89±0.10 | 77.14 |
| Infect matched group | 50 | Mix drink | 0 | - | - | 1.89±0.10 | 48.59 |
| The normal healthy controls group | 50 | Mix drink | 0 | - | - | 1.68±0.16 | 100.00 |
Above-mentioned result of the test shows that Drug therapy artificial challenge's of the present invention infectious bursal disease has good effect, and effective percentage reaches 80%～92%, and cure rate reaches 76%～85%, all is higher than control drug.The relative weight gain rate of in addition, drinking height of the present invention, middle dose groups is also apparently higher than medicine matched group and infection matched group.
Clinical efficacy test (two)
200 30 aa broiler chicken of picked at random (aseptic through physical examination) are divided into five groups, 40 every group.First group is healthy group, infective virus not, not administration; All the other four groups through doing experiment behind the strong malicious counteracting toxic substances of artificial challenge's 0.5mL bursal disease virus of chickens.Second group of negative control group, infective virus, not administration; The 3rd group is Chinese medicine preparation, and the 4th group is medicine of the present invention, and the 5th group is antipyretic and antitoxic powder (production of Shandong veterinary drug manufacturing enterprise), feeds by 3g/ chicken/sky spice.Concrete result of the test is seen table 2.
Table 2 Drug therapy chicken bursal disease of the present invention curative effect
| Numbering | Group | Mortality rate % | Cure rate % | Effective percentage % |
| First group | Healthy group | 0 | 100(40/40) | 100(40/40) |
| Second group | Negative control group | 55(22/40) | 0(0/40) | 45.0(18/40) |
| The 3rd group | The Chinese medicine preparation group | 21(9/40) | 45.0(18/40) | 79.0(31/40) |
| The 4th group | Drug group of the present invention | 10(4/40) | 87.5(35/40) | 92.5(37/40) |
| The 5th group | Antipyretic and antitoxic powder | 13(5/40) | 50.0(20/40) | 87.0(35/40) |
The result shows that drug group of the present invention and matched group difference highly significant (P＜0.01) explain that medicine of the present invention has significant therapeutical effect to chicken bursal disease, and than Chinese medicine preparation group, antipyretic and antitoxic powder group better efficacy.
Clinical efficacy test (three)
5000 of Xinxiang, Henan Province plant laying chickling; During raising to 35 age in days, take place to desire to increase to the disease of clinical symptoms, cut open inspection drumsticks portion, chest muscle has strip or ecchymosis to arrange yellow loose stool, serious dehydration, drink; The remarkable enlargement of fabricius bursa, a day mortality rate is 1%.Cut open diagnosis such as inspection according to clinical symptoms and pathology, be judged to be infectious bursal disease.The 2nd day of morbidity mixed drink with medicine of the present invention according to the ratio of 1mL/L, and 3 days state of an illness are controlled after the medication, and effective percentage reaches 92.66%.
Clinical efficacy test (four)
Jiaozhuo, Henan Province plant raises table hens 15000, when raising to 28 ages in days, takes place to desire to increase to the disease of clinical symptoms to arrange yellow loose stool, serious dehydration, drink.Cut open inspection: the remarkable enlargement of fabricius bursa, a day mortality rate is 0.8%, cuts open diagnosis such as inspection variation and Serological testing according to clinical symptoms, pathology, is judged to be infectious bursal disease.The 2nd day of morbidity mixed drink with medicine of the present invention according to the ratio of 1mL/L, and 3 days state of an illness are controlled after the medication, and effective percentage reaches 95%.
Clinical efficacy test (five)
Chicken bursal disease is a kind of acute contagious disease in 2～15 ages in week of being caused by bursal disease virus, with infringement fabricius bursa etc. lymphoid tissue generation immunosuppressant or immunodeficiency, and can the multiple disease of secondary, can cause great economic loss.More than 200 in five areas such as Xinyang, Henan, Zhoukou City, Zhumadian, Nanyang, Luohe morbidity chicken crowds of medicine of the present invention carry out drug test, treat 94612 of disease chickens altogether, cure 84492 altogether, and cure rate is 89.30%, and is evident in efficacy.
Medicine of the present invention is added up like table 3 curative effect of treatment bursal disease.
Table 3 medicine of the present invention is to the curative effect statistics of treatment bursal disease
| The area | Example number (only) | Cure number (only) | Cure rate % |
| Xinyang | 25869 | 22729 | 87.86 |
| The Luohe | 6579 | 5895 | 89.60 |
| Nanyang | 15963 | 14589 | 91.39 |
| Zhoukou City | 21415 | 18687 | 87.26 |
| Zhumadian | 24786 | 22572 | 91.06 |
| Add up to | 94612 | 84492 | 89.30 |
The present invention treats millions of of chicken bursal diseases, all obtains better curative effect, and general treatment can stop death after 2 days, can cure after 3～5 days, does not generally recur after the healing, shows that curative effect of medication of the present invention is remarkable, for numerous raisers create more economic benefit.
Claims (2)
1. mixture of treating infectious bursal disease, it is characterized in that: every 100g mixture is made up of following component:
Astragalus polysaccharides 1～10g
Taurine 3～12g
Aminophenazone 4～15g
Vitamin C 2～10g
Interferon inducers 0.04～0.2g
Ethanol 5～20g
Sodium benzoate 0.1～0.4g
Surplus is a water for injection;
Described interferon inducers is any one in polyinosini, hemagglutinin or the Tilorone.
2. the method for preparing of the mixture of treatment infectious bursal disease as claimed in claim 1 is characterized in that it carries out according to the following steps:
(1) get the half the water for injection of recipe quantity and be heated to 60 ℃, add taurine, vitamin C and the aminophenazone of recipe quantity successively, dissolving adds the ethanol of recipe quantity fully, forms solution;
(2) with the astragalus polysaccharides dissolving of water for injection, form solution with recipe quantity;
(3) with the sodium benzoate dissolving of water for injection, form solution with recipe quantity;
(4) with the interferon inducers dissolving of water for injection, form solution with recipe quantity;
(5) solution of combining step 1,2 and 3 gained is transferred pH to 6.0～7.0 with sodium hydroxide, slowly adds step 4 gained solution, and the limit edged stirs, and last water for injection standardize solution filters, and the aseptic subpackaged bottle of going into to sterilize gets final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100645941A CN101856495B (en) | 2009-04-09 | 2009-04-09 | Medical composition and mixture for treating chicken infectious bursal disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100645941A CN101856495B (en) | 2009-04-09 | 2009-04-09 | Medical composition and mixture for treating chicken infectious bursal disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101856495A CN101856495A (en) | 2010-10-13 |
| CN101856495B true CN101856495B (en) | 2012-06-06 |
Family
ID=42942799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100645941A Active CN101856495B (en) | 2009-04-09 | 2009-04-09 | Medical composition and mixture for treating chicken infectious bursal disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101856495B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228679B (en) * | 2011-06-15 | 2013-01-02 | 山东华辰生物科技有限公司 | Chicken interferon gamma combined medicament and application |
| CN102988404B (en) * | 2012-12-13 | 2014-07-23 | 江苏恒丰强生物技术有限公司 | Astragalus polysaccharide injection and preparation method thereof |
| CN104170790A (en) * | 2014-07-10 | 2014-12-03 | 江西天韵农业开发有限公司 | Raising method capable of improving growth performance of ducklings |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823936A (en) * | 2005-12-31 | 2006-08-30 | 天津生机集团 | Antivirus medicinal composition, preparation method and use |
| CN101422561A (en) * | 2007-11-02 | 2009-05-06 | 天津瑞普生物技术集团有限公司 | Traditional Chinese medicine oral liquid for treating poultry infectious bursal disease |
-
2009
- 2009-04-09 CN CN2009100645941A patent/CN101856495B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1823936A (en) * | 2005-12-31 | 2006-08-30 | 天津生机集团 | Antivirus medicinal composition, preparation method and use |
| CN101422561A (en) * | 2007-11-02 | 2009-05-06 | 天津瑞普生物技术集团有限公司 | Traditional Chinese medicine oral liquid for treating poultry infectious bursal disease |
Non-Patent Citations (2)
| Title |
|---|
| 张志美等.黄芪多糖治疗鸡传染性法氏囊病.《中国家禽》.2007,第29卷(第18期),43-44. * |
| 金凤等.黄芪多糖冲剂治疗鸡法氏囊病的临床试验.《养殖与饲料》.2007,(第9期),32-33. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101856495A (en) | 2010-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103230574B (en) | Traditional Chinese medical composition for treating porcine epizootic diarrhea and application thereof | |
| CN106822890A (en) | A kind of pharmaceutical composition for preventing and treating diarrhea of weaned piglets and its preparation method and application | |
| CN103006758A (en) | Chinese medicament composition for treating infectious bursal disease and preparation method thereof | |
| CN103860715B (en) | A kind of compound Chinese medicine extract and application thereof preventing and treating coccidiosis of domestic fowls | |
| CN101507762A (en) | Veterinary medicine for treating colibacillosis and white dysentery | |
| CN101856495B (en) | Medical composition and mixture for treating chicken infectious bursal disease and preparation method thereof | |
| CN102895326B (en) | Traditional Chinese medicine composition for treating infantile common cold and preparation method for traditional Chinese medicine composition | |
| CN104739963A (en) | Preparation method of Chinese medicinal micro-ecological oral preparation for preventing chicken colibaciuosis | |
| CN101259272A (en) | Yolk antibody feed additive and injection for resisting porcine reproductive and respiratory syndrome and preparation thereof | |
| CN101249113A (en) | Applications of ash tree flowers polysaccharide for preparing preventing and controlling fowl virosis medicament | |
| CN101259160B (en) | Compound preparations for treating birdsvirosis and preparation thereof | |
| CN109306009B (en) | Preparation method of anti-piglet toxigenic escherichia coli egg yolk antibody | |
| CN103285255A (en) | Anti-coccidiosis pharmaceutical composition as well as preparation method and use thereof | |
| CN109999117A (en) | Prevent and treat enteritis, bacillary dysentery, dysentery, intractable diarrhea Chinese medicine composition | |
| CN101439161A (en) | Composition for treating salmonellosis of chicken and preparation method | |
| CN101249097B (en) | Applications of ash tree flowers polysaccharide for preparing preventing and controlling pig virosis medicament | |
| CN101797345B (en) | Traditional Chinese medicine composition for preventing and treating viral diseases of poultry and preparation method | |
| CN103861007B (en) | A kind of Chinese herbal compound preparation for the treatment of chicken diarrhea | |
| CN104208683B (en) | The pharmaceutical composition of a kind of anti-duck viral disease, lyophilized powder, preparation method and application | |
| CN106214862A (en) | A kind of Traditional Chinese veterinary medicine oral solution preventing and treating the atypical newcastle of chicken and preparation method thereof | |
| CN102988548A (en) | Chinese medicinal composition with function of astringing intestine to stop diarrhea, preparation method thereof | |
| CN105998783A (en) | Traditional Chinese medicine oral liquid for treating hypoimmunity of chickens | |
| CN101780064B (en) | New application of p-hydroxyl cinnamic acid | |
| CN102091321A (en) | Medicament oral liquid for treating enteritis and diarrhea and preparation method thereof | |
| CN106266317A (en) | A kind of Chinese medicine preparation preventing and treating chickling bursal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200709 Address after: 451162, Henan, Zhengzhou province Xinzheng Xue Zhen Station Front Street Patentee after: HENAN HUITONG TIANXIA BIO-ENGINEERING Co.,Ltd. Address before: 450008, Henan, Zhengzhou by three road 28, Fung Garden A block, 5 floor, C households Patentee before: HENAN HUITONG TIANXIA ANIMAL PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |